Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous cytokine-induced killer cells/vaccinia virus DD-CDSR CRX100

A preparation of autologous cytokine-induced killer (CIK) cells that have been generated ex vivo from killer cells treated with cytokines and infected with the oncolytic vaccinia virus DD-CDSR (vvDD-CDSR; double-deleted vaccinia virus plus CD/SMR), with potential immunomodulatory and antineoplastic activities. CIK cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T lymphocytes. Upon infusion of autologous CIK cells/vvDD-CDSR CRX100, the CIK cells protect the oncolytic virus vvDD-CDSR from immune attack and enhance the delivery of the oncolytic virus to tumor cells. The oncolytic virus vvDD-CDSR preferentially targets and infects tumor cells causing oncolysis. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous CIK cells/vvDD-CDSR CRX100
Code name:CRX 100
CRX-100
CRX100
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search